Could Viagra, the widely used drug for erectile dysfunction, become part of the fight against cancer?

A new study suggests that sildenafil, commonly known by its brand name Viagra, may help slow the spread of cancer by limiting the ability of cancer cells to use cholesterol—an essential component that helps them migrate and form new tumors.

Researchers say the drug's anti-metastatic effects could become even stronger when combined with statins, which reduce cholesterol production. The findings, published in the journal Cancer Research, also indicate that patients taking sildenafil showed improved survival rates.

While the research is promising, scientists emphasize that more clinical studies are needed before Viagra can be recommended as a cancer treatment.

Viagra May Help Fight Cancer Spread? Scientists Discover Promising New Use for Sildenafil

The world of medicine is shifting. Artificial intelligence is helping identify potential drug molecules faster and cheaper than before. But can it fully replace the work of scientists? Experts say: No. Instead, AI can be a powerful assistant.<h2>How AI helps design new medicines</h2>AI scans huge datasets such as genes, proteins, and clinical trials to spot promising drug targets far more quickly than traditional methods. It can even create new molecules from scratch, a process called de novo drug design. Generative models like GANs and VAEs are already doing it. &nbsp;It lets companies explore vast chemical possibilities efficiently. In fact, the AI in drug discovery market sits at around US$1.5 billion in 2023 and is expected to grow to USD 20.3 billion by 2030, expanding at nearly 30 per cent annually as per the Grand View Research&nbsp;When tested, AI-designed drug candidates have shown an 80-90 per cent success rate in early (Phase I) clinical trials, much higher than usual.&nbsp; For example, a new antibiotic discovered by MIT using AI showed strong effects against MRSA and other drug-resistant bacteria in animal tests. Furthermore, a recent deal between Eli Lilly and the AI company Superluminal is worth up to US$1.3 billion to develop obesity treatments using AI tools as reported by Reuters&nbsp;<h2>Scientists still play a critical role</h2>Despite its speed and insight, AI has limitations. It lacks the creative intuition scientists bring to understanding disease biology, forming new research questions, and steering experiments.Ethical and safety concerns also matter AI can inherit biases from data, raise privacy issues, or misinterpret rare conditions. These need careful oversight from scientists.&nbsp;<h2>What lies ahead:&nbsp;</h2>

The most promising path combines AI’s speed with scientists’ expertise. Companies like MIT and Alphabet’s Isomorphic Labs use AI to design molecules while labs test them under close human supervision.

AI is speeding up drug discovery by designing new medicines faster and cheaper. It scans data, creates new molecules, and boosts success in early trials. But can it replace scientists? 

The world of medicine is shifting. Artificial intelligence is helping identify potential drug molecules faster and cheaper than before. But can it fully replace the work of scientists? Experts say: No. Instead, AI can be a powerful assistant. How AI helps design new medicines AI scans huge datasets such as genes, proteins, and clinical trials to spot promising drug targets far more quickly than traditional methods. It can even create new molecules from scratch, a process called de novo drug design. Generative models like GANs and VAEs are already doing it. It lets companies explore vast chemical possibilities efficiently. In fact, the AI in drug discovery market sits at around US$1.5 billion in 2023 and is expected to grow to USD 20.3 billion by 2030, expanding at nearly 30 per cent annually as per the Grand View Research When tested, AI-designed drug candidates have shown an 80-90 per cent success rate in early (Phase I) clinical trials, much higher than usual. For example, a new antibiotic discovered by MIT using AI showed strong effects against MRSA and other drug-resistant bacteria in animal tests. Furthermore, a recent deal between Eli Lilly and the AI company Superluminal is worth up to US$1.3 billion to develop obesity treatments using AI tools as reported by Reuters Scientists still play a critical role Despite its speed and insight, AI has limitations. It lacks the creative intuition scientists bring to understanding disease biology, forming new research questions, and steering experiments. Ethical and safety concerns also matter AI can inherit biases from data, raise privacy issues, or misinterpret rare conditions. These need careful oversight from scientists. What lies ahead:

AI is speeding up drug discovery by designing new medicines faster and cheaper. It scans data, creates new molecules, and boosts success in early trials. But can it replace scientists?&nbsp;

AI-designed medicines: Can algorithms replace scientists?

drug-discovery

Drug Discovery, News on Drug Discovery, stories on Drug Discovery, articles on Drug Discovery, Drug Discovery stories at Wion, Drug Discovery news, Drug Discovery latest news